论文部分内容阅读
目的:探讨原因不明复发性流产(URSA)主动免疫治疗质量控制以及疗效。方法:对505例URSA患者给予主动免疫治疗,于治疗前、治疗中及治疗后进行严格的质量控制,包括治疗前从业人员培训、患者基本资料的采集、适应证选择、知情同意等,治疗过程中样本采集与保存、实验室无菌操作,免疫治疗后进行疗效评估、随访。结果:经过严格的质量控制,减少了患者的不良反应;治疗中进行再次生育力的评估有利于指导妊娠。再次受孕325例,占免疫治疗人数的67.29%(325/483);未妊娠149例,占30.85%(149/483)。妊娠后加强免疫治疗并综合保胎,283例成功妊娠,占受孕总数的87.08%(283/325);42例再次流产,流产率为12.92%(42/325)。结论:URSA患者主动免疫治疗质量控制是保证疗效的有效措施。
Objective: To investigate the quality control and curative effect of active immunotherapy for unexplained recurrent spontaneous abortion (URSA). Methods: 505 active URSA patients were given active immunotherapy. Before and during treatment and after treatment, strict quality control including pre-treatment practitioners training, basic information collection, indications selection and informed consent were provided. In the sample collection and preservation, laboratory aseptic operation, the efficacy of immunotherapy after treatment, follow-up. Results: After strict quality control, patients’ adverse reactions were reduced. The evaluation of re-fertility during treatment was helpful for guiding pregnancy. 325 cases of conception again, accounting for 67.29% (325/483) of the number of immunotherapy; 149 cases of non-pregnancy, accounting for 30.85% (149/483). Pregnancy after intensive immunotherapy and miscarriage, 283 cases of successful pregnancy, accounting for 87.08% (283/325) of the total number of conception; 42 cases of miscarriage again, the abortion rate was 12.92% (42/325). Conclusion: The quality control of active immunotherapy in patients with URSA is an effective measure to ensure curative effect.